What is Impel Pharmaceuticals?
Impel Pharmaceuticals Inc. is a commercial-stage pharmaceutical company based in Seattle, Washington. The company is dedicated to the development of first-in-class intranasal drug treatments specifically designed for central nervous system (CNS) disorders. This focus positions Impel at the forefront of innovation in a critical area of medical need, aiming to provide novel therapeutic solutions for complex neurological conditions.
How much funding has Impel Pharmaceuticals raised?
Impel Pharmaceuticals has raised a total of $346.6M across 7 funding rounds:
Series B
$12M
Debt
$1.1M
Series C
$36M
Series D
$67.5M
Stock Offering
$80M
Debt
$50M
Other Financing Round
$100M
Series B (2015): $12M with participation from 3M New Ventures
Debt (2016): $1.1M, investors not publicly disclosed
Series C (2016): $36M supported by Vivo Capital, venBIO, and 5AM Ventures
Series D (2018): $67.5M featuring Vivo Capital, KKR & Co. (Kohlberg Kravis Roberts & Co.), venBio, 5AM Ventures, and Norwest Venture Partners
Stock Issuance/Offering (2021): $80M, investors not publicly disclosed
Debt (2021): $50M with participation from Silicon Valley Bank
Other Financing Round (2022): $100M led by Oaktree
Key Investors in Impel Pharmaceuticals
Oaktree
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments. The company is recognized for its opportunistic, value-oriented, and risk-controlled approach to investing across credit, equity, and real estate markets.
Vivo Capital
Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, is a global healthcare investment firm focused on private and public equity as well as venture capital.
KKR & Co. (Kohlberg Kravis Roberts & Co.)
KKR is a global investment firm investing across private markets in every asset class all over the world, KKR mission is to fortify companies and communities and help secure the futures of the institutions and individuals counting on us.
What's next for Impel Pharmaceuticals?
With the recent infusion of major strategic investment, Impel Pharmaceuticals is poised to accelerate its development pipeline and potentially advance its lead drug candidates toward commercialization. The substantial enterprise-level funding suggests a strategic focus on scaling operations, expanding clinical trials, and navigating the complex regulatory landscape. This capital will be instrumental in solidifying Impel's position in the competitive pharmaceutical market and bringing its innovative CNS treatments to patients.
See full Impel Pharmaceuticals company page
